Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
Affiliation
Department of Pharmacology and Toxicology ,School of Medicine ,Universidad Complutense de Madrid ,Madrid ,Spain